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In-vitro combination of arsenic trioxide and chemotherapy in small-cell lung cancer
CY Zheng, YL Kwong, JC Ho
Department of Medicine, The University of Hong Kong, Hong Kong
Introduction: Arsenic trioxide (ATO), an anti-tumour agent with multi-faceted mechanisms of action, has 
become a breakthrough treatment for acute promyelocytic leukaemia in recent years. There have been 
preliminary data about the potential activity of ATO in solid tumours, including small-cell lung cancer (SCLC). 
As SCLC is considered a chemo-sensitive malignancy, we conducted an in-vitro study examining the cytotoxic 
effects of ATO, clinically effective chemotherapeutic agents, or a combination of both in a SCLC cell line model.
Methods: Drug treatment (ATO, cisplatin, etoposide) experiments were performed in 4 SCLC cell lines (H-187, 
DMS-79, H-526, H-69) obtained from ATCC. The cancer cell viability was assessed by 3-(4,5-dimethyl-thiazoyl-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The proportion of apoptotic cell death was detected by 
Annexin-V/Propidium iodide assay with flow cytometry. The effects of combination treatment were determined 
by isobologram analysis using standard computer software (CalcuSyn, Biosoft, US).
Results: All the SCLC cell lines reacted to ATO and traditional chemotherapeutic reagents in time- and 
dose-dependent way. Two of them (H-187, H-526) were sensitive to ATO (eg IC50[48 hr]=2.4±0.35 µM and 
IC50[48hr]=2±0.21 µM), while the other two SCLC cell lines, DMS-79 and H-69, were resistant to either ATO (eg 
IC50[48hr]=12.3±1.5 µM and 10±3.7 µM) or chemotherapeutic agents (IC50=10-50 µM). Moderate synergistic 
cytotoxicity or additive effect were found in ATO and cisplatin combination treatment either in sensitive or 
resistant cell lines (CI=0.5-0.9). On the other hand, antagonistic interaction was shown in the combination of 
ATO and etoposide in all 4 cell lines (CI= 0.9-2).
Conclusion: Combination of ATO and cisplatin was synergistic in chemo-sensitive and additive in chemo-
resistant SCLC models. However, the combination of ATO and etoposide has resulted in antagonism. Further 
study is needed to determine the possibility and best schedule of combination treatment of ATO with existing 
standard chemotherapy.
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‘Yin-Yang’ regulation of insulin signalling by APPL1 and APPL2 in skeletal muscle cells
WD Zhu1, KK Cheng1, Y Wang2, KSL Lam1, A Xu1,2
1Department of Medicine, The University of Hong Kong, Hong Kong
2Department of Pharmacology, The University of Hong Kong, Hong Kong
Introduction: APPL1 and APPL2 are two intracellular adapter proteins containing a PH domain, a PTB domain, 
and a Leucine zipper motif. A growing body of evidence suggests that APPL1 acts as a key signalling molecule 
integrating multiple signalling stimuli. We have recently demonstrated that APPL1 potentiates insulin actions 
in liver and adipose tissue. However, the physiological functions and the underlying molecular mechanisms of 
APPL1 and APPL2 in regulating insulin actions in skeletal muscle have not been explored. The objective of this 
study was to investigate the role of APPLs in insulin signalling and downstream glucose uptake in both cultured 
myocytes and rodent models.
Methods: Proteins physically associated with APPL1 or APPL2 were retained by affinity purification and co-
immunoprecipitation, followed by mass spectrometry–based proteomic identification. The key domains of 
APPL2 involved in its interaction with APPL1 and TBC1D1 were determined by progressive truncation and 
site directed mutagenesis. Effects of APPL1 and APPL2 in regulating insulin signalling were measured by Akt 
phosphorylation and in-vitro or ex-vivo glucose uptake assay.
Results: Overexpression of APPL2 inhibits insulin-stimulated Akt phosphorylation leading to down-regulation of 
glucose uptake in C2C12 myotubes and in skeletal muscle of the APPL2 transgenic mice. In contrast, suppressing 
APPL2 expression by RNAi significantly enhances insulin-stimulated Akt phosphorylation and glucose uptake 
in C2C12 myotubes. However, APPL1 exerts opposite effects in regulating insulin signalling in muscles compared 
to APPL2. Co-immunoprecipitation assay followed by western blot analysis revealed the interaction of TBC1D1 
with APPL2 but not APPL1. Furthermore, the interaction occurs in the N-terminal PTB domain of TBC1D1 and 
N-terminal BAR domain of APPL2. The binding of APPL2 to TBC1D1 was enhanced by insulin-stimulated Akt 
activation, and suppressed by overexpression of APPL1.
Conclusion: APPL1 and APPL2 act as a pair of ‘Yin-and-Yang’ molecules critically involved in the regulation of 
insulin signalling and glucose uptake in skeletal muscle. Further investigations on these two proteins might 
lead to the identification of novel regulatory mechanisms that underlie insulin resistance and diabetes.
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